CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-α2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC)

被引：10

作者：

Marten, A.

Schmidt, J.

Debus, J.

Harig, S.

Lindel, K.

Klein, J.

Bartsch, D. K.

Capussotti, L.

Zuelke, C.

Buchler, M.

机构：

[1] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[2] Heidelberg Univ, Dept Surg, Heidelberg, Germany

[3] Heidelberg Univ, Dept Radiooncol, Heidelberg, Germany

[4] Heidelberg Univ, Dept Surg, Natl Ctr Tumor Dis, Heidelberg, Germany

[5] Stadt Kliniken Bielefeld Mitte, Dept Radiooncol, Bielefeld, Germany

[6] Stadt Kliniken Bielefeld Mitte, Dept Surg, Bielefeld, Germany

[7] Mauriziano Hosp, Unit Hepatobiliary Pancreat Surg, Turin, Italy

[8] Univ Hosp Regensburg, Dept Surg, Regensburg, Germany

来源：

关键词：

D O I：

10.1200/jco.2010.28.18_suppl.lba4012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4012

引用

页数：1